PureTech HealthPRTCY +1.49%62 Buyback Yield % is 0.45 as of Jun. 24, 2026, which is 32% below its 10-year median of 0.66. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 745 Biotechnology companies, PureTech Health ranks better than 91.01% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for PureTech Health's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, PureTech Health's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where PureTech Health's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a Buyback Yield % of 0.45 as of Jun. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PureTech Health and its competitors. This is 32% below median its historical median of 0.66. According to the industry distribution chart, PureTech Health ranks #67 out of 745 companies in the Biotechnology industry, placing it in the top 9%.
Is PureTech Health's Buyback Yield % too high?
PureTech Health's current Buyback Yield % of 0.45 is 32% below median its 10-year median of 0.66. Based on the distribution chart, PureTech Health ranks #67 out of 745 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #67 out of 745 companies for Buyback Yield %. This places PureTech Health in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PureTech Health and its competitors. PureTech Health's current Buyback Yield % is 0.45, which is 32% below median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Buyback Yield % is 0.45, which is 32% below median its 10-year median of 0.66. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Buyback Yield % is 0.45 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
Buyback Yield %: 0.45 (32% below median its 10-year median of 0.66)
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
